Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03735446
Title Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Cytarabine + Etoposide + Mitoxantrone + Prexasertib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.